文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌分子亚型对预测新辅助化疗后反应与生存的影响

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
PubMed 文献 · Eur Urol · 2017-04-05

研究对343例肌层浸润性膀胱癌患者的新辅助化疗前经尿道切除标本进行全转录组分析,按四种已发表方法分型,并开发单样本基因组分型分类器(GSC)预测四种共识亚型。GSC预测准确率73%,基底样肿瘤从新辅助化疗中总生存获益最大,但研究为回顾性设计且跨数据集比较。

要点

  • GSC可高准确率(73%)预测四种共识分子亚型,并在独立新辅助化疗与非新辅助化疗数据集中验证其临床意义。
  • 管腔型肿瘤无论是否接受新辅助化疗总生存均最佳,密蛋白低型肿瘤无论治疗方案总生存均差。
  • 基底样肿瘤接受新辅助化疗较单纯手术总生存改善最大,作者认为若获进一步验证应优先考虑基底样肿瘤患者接受新辅助化疗。

核心结论

  • 分子分型可能影响患者从新辅助化疗中的获益,若在额外研究中验证,作者建议基底样肿瘤患者应优先接受新辅助化疗。
  • 研究发现了首个可用于肌层浸润性膀胱癌分型的单样本分类器,可能适合整合入常规临床实践。

研究设计与样本

  • 对343例肌层浸润性膀胱癌患者新辅助化疗前经尿道切除标本进行全转录组分析,按四种已发表分子分型方法分类。
  • 开发单样本基因组分型分类器(GSC)预测四种共识亚型(密蛋白低型、基底型、管腔浸润型、管腔型),并与476例非新辅助化疗病例(已发表数据集)的总生存进行比较。
  • 采用受试者工作特征曲线确定GSC准确性,采用Cox比例风险回归模型估计GSC对生存的影响。

主要发现

  • GSC预测四种共识分子亚型的准确率为73%,预测的共识亚型的临床意义可在独立新辅助化疗和非新辅助化疗数据集中验证。
  • 管腔型肿瘤无论是否接受新辅助化疗总生存均最佳;密蛋白低型肿瘤无论治疗方案总生存均差。
  • 基底样肿瘤接受新辅助化疗较单纯手术总生存改善最大。

关键数值与推荐

  • GSC预测四种共识分子亚型的准确率为73%。
  • 研究纳入343例肌层浸润性膀胱癌患者的新辅助化疗前标本,并与476例非新辅助化疗病例比较总生存。

临床怎么用

  • 作者认为若在额外研究中验证,基底样肿瘤患者应优先接受新辅助化疗。
  • 作者认为新发现的分类器可在单个患者中识别分子亚型,并可在进一步验证后整合入常规临床实践。

局限性

  • 研究的主要局限性为回顾性设计和跨数据集比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An early report on the molecular subtyping of muscle-invasive bladder cancer (MIBC) by gene expression suggested that response to neoadjuvant chemotherapy (NAC) varies by subtype. OBJECTIVE: To investigate the ability of molecular subtypes to predict pathological downstaging and survival after NAC. DESIGN, SETTING, AND PARTICIPANTS: Whole transcriptome profiling was performed on pre-NAC transurethral resection specimens from 343 patients with MIBC. Samples were classified according to four published molecular subtyping methods. We developed a single-sample genomic subtyping classifier (GSC) to predict consensus subtypes (claudin-low, basal, luminal-infiltrated and luminal) with highest clinical impact in the context of NAC. Overall survival (OS) according to subtype was analyzed and compared with OS in 476 non-NAC cases (published datasets). INTERVENTION: Gene expression analysis was used to assign subtypes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Receiver-operating characteristics were used to determine the accuracy of GSC. The effect of GSC on survival was estimated by Cox proportional hazard regression models. RESULTS AND LIMITATIONS: The models generated subtype calls in expected ratios with high concordance across subtyping methods. GSC was able to predict four consensus molecular subtypes with high accuracy (73%), and clinical significance of the predicted consensus subtypes could be validated in independent NAC and non-NAC datasets. Luminal tumors had the best OS with and without NAC. Claudin-low tumors were associated with poor OS irrespective of treatment regimen. Basal tumors showed the most improvement in OS with NAC compared with surgery alone. The main limitations of our study are its retrospective design and comparison across datasets. CONCLUSIONS: Molecular subtyping may have an impact on patient benefit to NAC. If validated in additional studies, our results suggest that patients with basal tumors should be prioritized for NAC. We discovered the first single-sample classifier to subtype MIBC, which may be suitable for integration into routine clinical practice. PATIENT SUMMARY: Different molecular subtypes can be identified in muscle-invasive bladder cancer. Although cisplatin-based neoadjuvant chemotherapy improves patient outcomes, we identified that the benefit is highest in patients with basal tumors. Our newly discovered classifier can identify these molecular subtypes in a single patient and could be integrated into routine clinical practice after further validation.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Seiler R, Ashab HAD, Erho N, et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017. PMID: 28390739. doi:10.1016/j.eururo.2017.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。